Douglas Scott Reintgen

Q: What Schools Are Affiliated With Douglas Scott Reintgen

Douglas Scott Reintgen is affiliated with the following schools: University of Sydney, University of Louisville, University of South Florida, Duke University, University of Texas Southwestern Medical Center

Douglas Scott Reintgen's AcademicInfluence.com Rankings

Philosophy

#8727

World Rank

#12162

Historical Rank

Logic

#5753

World Rank

#7178

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Douglas Scott Reintgen's Degrees

Doctorate Medicine University of North Carolina at Chapel Hill
PhD Cancer Biology University of North Carolina at Chapel Hill

Why Is Douglas Scott Reintgen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Douglas Scott Reintgen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001) (2651)
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. (2001) (2315)
Sentinel-node biopsy or nodal observation in melanoma. (2006) (1348)
Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. (1996) (1323)
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. (1999) (1230)
Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. (1999) (779)
The Orderly Progression of Melanoma Nodal Metastases (1994) (733)
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. (2011) (645)
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. (2007) (612)
Sentinel Node Biopsy for Early-Stage Melanoma: Accuracy and Morbidity in MSLT-I, an International Multicenter Trial (2005) (589)
Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial (2006) (530)
Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. (1996) (505)
Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. (1998) (491)
Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. (1998) (450)
A new American Joint Committee on Cancer staging system for cutaneous melanoma (2000) (428)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth (2002) (426)
An Evidence‐based Staging System for Cutaneous Melanoma 1 (2004) (420)
Molecular staging of malignant melanoma: correlation with clinical outcome. (1998) (351)
Sentinel-lymph-node biopsy for breast cancer--not yet the standard of care. (1998) (306)
Influence of physician communication on newly diagnosed breast patients' psychologic adjustment and decision‐making (1994) (301)
Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy (1996) (297)
Complications Associated With Sentinel Lymph Node Biopsy for Melanoma (2003) (289)
Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin (1998) (287)
Detection of Submicroscopic Lymph Node Metastases with Polymerase Chain Reaction in Patients with Malignant Melanoma (1994) (261)
Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. (2001) (255)
Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. (1993) (254)
Sentinel Lymph Node Biopsy for Melanoma: How Many Radioactive Nodes Should be Removed? (2001) (249)
Lessons learned from the Sunbelt Melanoma Trial (2004) (237)
Importance of Lymphatic Mapping in Ductal Carcinoma in Situ (DCIS): Why Map DCIS? (2001) (232)
Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. (1991) (228)
Correlation Between Prognostic Factors and Increasing Age in Melanoma (2004) (213)
The role of sentinel lymph node biopsy in breast cancer. (1999) (211)
Sentinel Node Biopsy in Ductal Carcinoma In Situ Patients (2000) (210)
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. (2011) (195)
Lethal “Thin” Malignant Melanoma: Identifying Patients at Risk (1988) (193)
The Impact on Morbidity and Length of Stay of Early Versus Delayed Complete Lymphadenectomy in Melanoma: Results of the Multicenter Selective Lymphadenectomy Trial (I) (2010) (188)
Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. (2001) (185)
Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. (2001) (175)
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. (1983) (173)
Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. (2001) (171)
Sentinel Lymph Node Biopsy for Head and Neck Melanomas (2003) (164)
Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I) (2012) (163)
Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. (1984) (158)
Is incisional biopsy of melanoma harmful? (2005) (155)
Sentinel Lymph Node Biopsy in Melanoma of the Head and Neck (1997) (153)
Recent advances in the care of the patient with malignant melanoma. (1997) (151)
Gender-Related Differences in Outcome for Melanoma Patients (2006) (141)
Patterns of early recurrence after sentinel lymph node biopsy for melanoma. (2002) (139)
Interval sentinel lymph nodes in melanoma. (2002) (137)
Age and Body Mass Index May Increase the Chance of Failure in Sentinel Lymph Node Biopsy for Women with Breast Cancer (2002) (135)
Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma (1998) (135)
Lymphatic Mapping and Sentinel Lymph Node Biopsy (1999) (132)
Malignant melanoma arising during pregnancy. A study of 100 patients. (1990) (130)
Clinical patterns of metastasis (2006) (130)
Pathologic examination of the sentinel lymph node in malignant melanoma. (1999) (129)
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. (2003) (128)
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. (2006) (128)
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. (2008) (122)
Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study (2006) (121)
Bleomycin-mediated electrochemotherapy of metastatic melanoma. (1996) (119)
Tumor Biology of Infiltrating Lobular Carcinoma: Implications for Management (1995) (113)
A Pilot Study Utilizing Intraoperative Lymphoscintigraphy for Identification of the Sentinel Lymph Nodes in Vulvar Cancer (1997) (112)
Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. (2000) (111)
Recurrent malignant melanoma: the identification of prognostic factors to predict survival. (1992) (109)
Malignant melanoma and pregnancy (1985) (108)
Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. (1997) (108)
Malignant melanoma in black American and white American populations. A comparative review. (1982) (102)
Touch preparation cytology of breast lumpectomy margins with histologic correlation. (1991) (101)
Bleomycin-mediated electrochemotherapy of basal cell carcinoma. (1996) (97)
Factors Associated with False-Negative Sentinel Lymph Node Biopsy in Melanoma Patients (2009) (97)
Implementation of New Surgical Technology: Outcome Measures for Lymphatic Mapping of Breast Carcinoma (1999) (95)
Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. (1995) (95)
Lymphoscintigraphy in malignant melanoma. (1992) (94)
Current status of sentinel lymph node mapping and biopsy: facts and controversies. (2003) (94)
Age as a prognostic factor in the malignant melanoma population (1994) (93)
Microstaging of Breast Cancer Patients Using Cytokeratin Staining of the Sentinel Lymph Node (1999) (91)
The Use of Intraoperative Radiolymphoscintigraphy for Sentinel Node Biopsy in Patients with Malignant Melanoma (1996) (91)
Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma (1997) (90)
Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. (2007) (89)
Lymphatic mapping in the treatment of breast cancer. (1998) (88)
Sentinel Node Biopsy and Cytokeratin Staining for the Accurate Staging of 478 Breast Cancer Patients (1999) (87)
The use of lymphoscintigraphy in melanoma of the head and neck. (1994) (85)
Prognosis for recurrent stage I malignant melanoma. (1987) (84)
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. (2008) (84)
Improved Staging of Node-Negative Patients With Intermediate to Thick Melanomas (>1 mm) With the Use of Lymphatic Mapping and Sentinel Lymph Node Biopsy (2001) (84)
The Progression of Melanoma Nodal Metastasis Is Dependent on Tumor Thickness of the Primary Lesion (1999) (84)
Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. (2010) (83)
Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. (2001) (82)
Metastatic malignant melanoma with an unknown primary. (1983) (76)
Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. (2003) (76)
Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes (1998) (67)
Tumor biology of infiltrating lobular carcinoma. Implications for management. (1995) (66)
A pilot study utilizing intraoperative lymphoscintigraphy for identification of the sentinel lymph nodes in vulvar cancer. (1998) (63)
Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer (1998) (61)
Multiple primary melanomas: Implications for screening and follow-up programs for melanoma (2006) (61)
The effects of postinjection massage on the sensitivity of lymphatic mapping in breast cancer. (2001) (59)
Breast cancer patients' personality style, age, and treatment decision making (1996) (58)
The tumor biology of melanoma nodal metastases. (1996) (58)
Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. (2002) (57)
Detection of submicroscopic lymph node metastases in patients with melanoma. (1991) (56)
ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. (2010) (55)
Clinical relevance of internal mammary node mapping as a guide to radiation therapy. (2001) (55)
Breast Cancer in Patients with Prior Augmentation: Presentation, Stage, and Lymphatic Mapping (2004) (55)
Metastatic melanoma: chemotherapy to biochemotherapy. (2002) (54)
Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? (2010) (52)
Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. (2016) (52)
Radioguidance for nonpalpable primary lesions and sentinel lymph node(s). (2001) (52)
Learning curves and breast cancer lymphatic mapping: institutional volume index. (2001) (50)
Utility of Internal Mammary Lymph Node Removal When Noted by Intraoperative Gamma Probe Detection (2001) (50)
The anatomy of missed breast cancers. (1993) (50)
Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. (2000) (49)
Final results of the department of defense multicenter breast lymphatic mapping trial (2002) (49)
Learning curves and certification for breast cancer lymphatic mapping. (1999) (47)
Clinical approach to neuroendocrine carcinoma of the skin (Merkel cell carcinoma). (2000) (46)
Ulceration as a Predictive Marker for Response to Adjuvant Interferon Therapy in Melanoma (2010) (45)
Final results of the Sunbelt Melanoma Trial (2008) (44)
Frequency of nonsentinel lymph node metastasis in melanoma (2007) (43)
Molecular mechanisms of metastasis (2006) (42)
Immunotherapy for melanoma. (2002) (42)
Second Primary Melanomas: Incidence and Outcome (2010) (41)
Sentinel Node Biopsy in Breast Cancer: An Overview (2000) (41)
Cutaneous malignant melanoma. (2001) (41)
Local recurrence of breast cancer after cytological evaluation of lumpectomy margins. (1998) (41)
The clinical relevance of molecular staging for melanoma. (2001) (40)
National trials involving lymphatic mapping for melanoma: the Multicenter Selective Lymphadenectomy Trial, the Sunbelt Melanoma Trial, and the Florida Melanoma Trial. (2004) (40)
The Role of Selective Lymphadenectomy in the Management of Patients with Malignant Melanoma (1995) (39)
The Role of Lymphoscintigraphy in the Management of the Patient With Breast Cancer (2001) (39)
The new melanoma staging system. (2002) (38)
Prognosis in malignant melanoma. (1998) (38)
Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. (1999) (37)
Lymphatic Mapping with Sentinel Lymph Node Biopsy in Patients with Breast Cancers <1 centimeter (T1A - T1B) (1999) (37)
Thymolipoma in association with myasthenia gravis. (1978) (37)
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). (2017) (37)
Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. (2014) (36)
Sex related survival differences in instances of melanoma. (1984) (36)
Identification of lymphatic drainage basins in patients with cutaneous melanoma. (1993) (33)
The use of selective lymphadenectomy in squamous cell carcinoma of the wrist: a case report. (1997) (33)
Sentinel lymphadenectomy: a safe answer to less axillary surgery? (1998) (33)
Cytology of lumpectomy specimens. (1991) (33)
Techniques for lymphatic mapping in breast carcinoma. (1999) (33)
Bilaterality and recurrence rates for lobular breast cancer: Considerations for treatment (1997) (33)
Parotid selective lymphadenectomy in malignant melanoma. (1999) (32)
Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcome (1997) (32)
Radioguided surgery for the ultrastaging of the patient with melanoma. (1997) (32)
Evaluation of new putative tumor markers for melanoma (1996) (30)
The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. (2004) (30)
Cutaneous melanoma of the head and neck. A review of 399 cases. (1983) (30)
The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma (2010) (30)
Psychosocial aspects of melanoma. (1992) (30)
Lymphatic mapping in breast cancer. (1999) (29)
Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. (1998) (29)
Cutaneous Melanoma of the Head and Neck: Advances in Evaluation and Treatment (2000) (28)
More rational and conservative surgical strategies for malignant melanoma using lymphatic mapping and sentinel node biopsy techniques. (1996) (27)
Diversity of Stage III Melanoma in the Era of Sentinel Lymph Node Biopsy (2013) (27)
Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up (2010) (27)
Evidence for a Better Nodal Staging System for Melanoma: The Clinical Relevance of Metastatic Disease Confined to the Sentinel Lymph Nodes (2013) (26)
Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. (2007) (26)
Diseases of the Liver 6th Ed (1988) (26)
Identification of submicroscopic lymph node metastases in patients with malignant melanoma. (1993) (26)
The Number of Lymph Nodes Involved with Metastatic Disease Does Not Affect Outcome in Melanoma Patients as Long as All Disease Is Confined to the Sentinel Lymph Node (2009) (25)
Lymphoscintigraphy as a predictor of lymphatic drainage from cutaneous melanoma (2006) (24)
The role of sentinel lymph node mapping for melanoma. (1997) (24)
The process of clinical trials: a model for successful clinical trial participation. (2001) (24)
Controversial topics in breast lymphatic mapping. (2004) (23)
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. (2006) (23)
Breast preservation in women with giant juvenile fibroadenoma. (2013) (23)
Radiologic imaging in malignant melanoma: a review. (1993) (23)
The promise of microarray technology in melanoma care. (2002) (22)
Sentinel node excision for the diagnosis of metastatic neuroendocrine carcinoma of the skin: a case report. (1997) (22)
Metastatic melanoma with an unknown primary. (1992) (22)
Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. (1997) (21)
Importance of race on breast cancer survival (2006) (21)
In support of sentinel node biopsy as a standard of care for patients with malignant melanoma. (2000) (21)
Etiology and prognosis of local recurrence in malignant melanoma of the skin. (1992) (21)
Sentinel lymph node micrometastasis from melanoma (1999) (21)
A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line treatment for patients with unresectable or metastatic melanoma (2011) (21)
The evaluation of putative tumor markers for malignant melanoma. (1992) (20)
Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects (2008) (20)
Fine needle aspiration biopsy of palpable breast lesions. Review and statistical analysis of 1875 cases. (1993) (20)
Breast Lymphatic Mapping and Sentinel Lymph Node Biopsy: State of the Art: 2015. (2016) (20)
Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5 (1983) (20)
The staging of malignant melanoma and the florida melanoma trial (2004) (19)
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. (1992) (19)
Radiologic, endoscopic and surgical considerations of malignant melanoma metastatic to the small intestine. (1984) (19)
Prevalence of Additional Positive Lymph Nodes in Complete Lymphadenectomy Specimens after Positive Sentinel Lymphadenectomy Findings for Early-Stage Melanoma of the Head and Neck (2003) (19)
Adherence to the National Quality Forum (NQF) Breast Cancer Measures Within Cancer Clinical Trials: A Review From ACOSOG Z0010 (2010) (18)
Erratum to: Axillary Recurrence Rate Following Negative Sentinel Node Biopsy for Invasive Breast Cancer: Long-Term Follow-Up (2010) (18)
Detection of occult melanoma cells in sentinel lymph nodes and blood. (1997) (18)
Lymphatic mapping and sentinel node harvest for malignant melanoma (1997) (18)
Molecular analysis in evaluating the sentinel node in malignant melanoma. (2001) (18)
Importance of Missed Axillary Micrometastases in Breast Cancer Patients (2001) (17)
Malignant melanoma in the American black. (1983) (17)
Comparison of Psychological Symptoms of Women Requesting Removal of Breast Implants with Those of Breast Cancer Patients and Healthy Controls (1997) (17)
Regional node dissection for melanoma: techniques and indication. (2007) (17)
Regional Nodal Surgery for Melanoma Impacts Recurrence Rates and Survival (2000) (16)
Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma (2011) (16)
Analysis of residual cancer after diagnostic breast biopsy: An argument for fine-needle aspiration cytology (1995) (16)
Isolated limb perfusion for recurrent melanoma of the extremity. (1992) (16)
Lymphoscintigraphy for malignant melanoma. Surgical considerations. (1983) (16)
Factors influencing accrual to ACOSOG Z0011, a randomized phase III trial of axillary dissection vs. observation for sentinel node positive breast cancer. (2006) (16)
The expanding role of lymphoscintigraphy in the management of cutaneous melanoma. First Place Winner: Conrad Jobst award. (1989) (16)
Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. (1998) (16)
Imprint cytology of needle-localized breast lesions. (1993) (16)
Investment in new technology research can save future health care dollars. (1997) (16)
The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up (2012) (15)
Histopathologic study of recurrent Clark level II melanomas. (1993) (15)
Clinical response to hormone therapy correlated with estrogen receptor analyses. Biochemical v histochemical methods. (1984) (15)
Immunohistochemical assessment of tumor vascularity in recurrent Clark II melanomas using antibody to type IV collagen (1995) (15)
The current management and prognosis of acral lentiginous melanoma. (1992) (14)
The medical legal implications of following mammographic breast masses. (1993) (14)
Redefining cutaneous lymphatic flow: the necessity of preoperative lymphoscintigraphy in the management of malignant melanoma. (1997) (14)
Lymphatic mapping and sentinel lymph node biopsy for breast cancer. (2002) (13)
Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. (1998) (13)
Juvenile malignant melanoma of the head and neck (1988) (13)
Lymphatic mapping: a technique providing accurate staging for breast cancer (1999) (13)
The changing face of malignant melanoma (2010) (12)
Melanoma nodal metastases: biologic significance and therapeutic considerations. (1996) (12)
Detection of occult lymph node metastases in malignant melanoma. (1992) (12)
Worldwide experience with lymphatic mapping for invasive breast cancer. (2004) (12)
Radioguided surgery for melanoma. (1999) (12)
Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma (1998) (12)
Renal artery stenosis in children. (1981) (12)
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. (1999) (12)
Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion (2010) (12)
Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials (2018) (11)
Advances in local-regional treatment for patients with early-stage breast cancer: a review of the field. (2010) (11)
Sentinel lymph node biopsy for breast cancer: Combined dye-isotope technique (2000) (11)
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. (1992) (11)
The role of elective lymph node dissection in malignant melanoma: who should undergo this nodal staging procedure? (1999) (11)
Malignant melanoma and the prognostic implications of pregnancy, oral contraceptives, and exogenous hormones. (1993) (11)
Chemotherapy for stage 4 melanoma: a three-year experience with cisplatin, DTIC, BCNU, and tamoxifen. (1993) (11)
Natural history and clinical evaluation of the lumpectomy scar. (1993) (11)
The concept of lymph node dissections in patients with malignant melanoma. (1992) (10)
The Training of Surgeons in America (2001) (10)
Pleomorphic lobular carcinoma in situ: treatment options for a new pathologic entity. (2012) (10)
Changing standards of surgical care for the melanoma patient (1996) (10)
The clinical relevance of sentinel lymph nodes identified with radiolymphoscintigraphy. (1997) (10)
The effectiveness of skin cancer screening and continuing medical education programs toward increasing the survival of patients with malignant melanoma. (1992) (10)
Transplantation of insulinoma into the diabetic Syrian hamster. (1980) (9)
Accurate staging of women with breast cancer (2002) (9)
The role of lymphoscintigraphy in lymphatic mapping for melanoma and breast cancer. (1998) (9)
Psychoneuroimmunology and Immune System Link for Stress, Depression, Health Behaviors, and Breast Cancer (1998) (9)
Cutaneous Lymphatic Drainage in Patients With Grossly Involved Nodal Basins (1999) (9)
Prevention and early detection of melanoma: a surgeon's perspective. (1993) (8)
National protocols for lymphatic mapping. (1999) (8)
The Next Revolution in General Surgery: Radioguided Surgery (1999) (8)
Emerging Evidence for a Survival Benefit Associated With Regional Lymph Node Dissection for Melanoma (2000) (8)
Molecular Staging of Melanoma (2004) (8)
Molecular staging for patients with malignant melanoma. (2007) (8)
Patterns of metastasis in human solid cancers. (2007) (7)
Lymphatic mapping for melanomas of the upper extremity. (1999) (7)
A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. (2010) (7)
Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging (2019) (7)
Effect of Lymphatic Mapping on Diagnosis and Treatment of Patients With T1a, T1b Favorable Breast Cancer (2003) (7)
Breast cancer screening in childhood cancer survivors. (2000) (6)
Treatment of the primary in malignant melanoma of the skin. (1992) (6)
The adjuvant treatment of malignant melanoma. (1997) (6)
Historical perspectives and future applications. (1999) (6)
Current management of melanoma patients with nodal metastases (2021) (6)
Prognostic significance of the sentinel lymph node (SLN) in stage I or II melanoma patients: 368 (1997) (6)
Hyperthermic isolated limb perfusion for extremity sarcomas. (2001) (6)
In vivo and in vitro binding of iodinated monoclonal antibody A2B5 to RIN insulinoma cells. (1983) (6)
IMMUNOLOGICAL CONSEQUENCES OF TRANSPLANTING RAT INSULINOMAS (1980) (5)
Establishing a Standard of Care for the Patient with Melanoma (2001) (5)
Localization Methods for Excisional Biopsy in Women With Nonpalpable Mammographic Abnormalities (2017) (5)
A myocutaneous flap for closure of upper arm amputations for uncontrolled axillary tumors (1991) (5)
Lymphatic mapping for melanoma before and after wide local excision: 367 (1997) (5)
Computer database for melanoma registry. A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. (1996) (5)
Localization of malignant melanoma using monoclonal antibodies. (1991) (5)
Florida's undeclared epidemic: malignant melanoma. (1997) (5)
Use Pre- and Intra-Operative Data To Predict Probability of Positive Non-Sentinel Lymph Nodes. (2009) (5)
Cytochemistry of sex steroid receptors: A critique (2005) (4)
Experimental trials of immunotherapy for malignant melanoma. (1991) (4)
Role of fine needle aspiration cytology after lumpectomy. (1994) (4)
The Florida Melanoma Trial I: A Prospective Multi-center Phase I/II Trial of Post-operative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-alpha in the Treatment of Advanced Stage III Melanoma (2008) (4)
Metastatic melanoma to regional lymph nodes. (2000) (4)
Expanding Indications for Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Breast Cancer Population (2001) (4)
Molecular staging for melanoma and breast cancer. (1999) (4)
Sentinel lymph node biopsy: results to date (2003) (4)
Extracapsular Extension in the Sentinel Lymph Node: Guidelines for Therapy. (2016) (4)
Computer database for melanoma: a clinical management and research tool to ensure continuous quality assessment. (1993) (3)
Nodal failure after lymphatic mapping (LM) and negative sentinel lymph node (SLN) biopsy in stage I or II melanoma patients: 101 (1997) (3)
The results of complete lymph node dissections in 88 melanoma patients with positive sentinel nodes: 365 (1997) (3)
The human genome project: a dream becoming a reality. (1999) (3)
A melanoma vaccine that works? Evidence for a phase III national trial (1998) (2)
Surgery for Melanoma Metastatic to the Gastrointestinal Tract (1999) (2)
A molecular technique useful in the detection of occult metastases in patients with melanoma : rt-PCR analysis of sentinel lymph nodes and peripheral blood. (2001) (2)
Lymphatic Mapping and Sentinel Node Biopsy in Breast Cancer-Reply (1997) (2)
Medical-legal pitfalls for the breast surgeon: incomplete mammographic localization of suspicious lesions and the correlation between palpable and mammographic abnormalities. (1996) (2)
Monoamine oxidase and catechol-o-methyltransferase activity in hamster and rat insulinomas (1979) (2)
Hyperthermic isolated limb perfusion: evolving concepts in the treatment of extremity soft tissue sarcomas (2006) (2)
Male Breast Cancer (2016) (1)
Superficial Femoral Lymph Node Dissection After Positive Sentinel Lymphadenectomy for Early-Stage Melanoma of the Lower Extremity (2003) (1)
The credentialing of American surgery (1997) (1)
Is the clinically positive axilla in breast cancer really a contraindication to sentinel node biopsy (2005) (1)
Innovative Cancer Screening Legislation (1992) (1)
Abstract OT3-4-02: MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I (2012) (1)
Prognostic F actors A nalysis o f 1 7,600 M elanoma P atients: Validation o f t he A merican J oint C ommittee o n C ancer Melanoma S taging S ystem (2001) (1)
Parotid gland sentinel lymphadenectomy in malignant melanoma: 142 (1997) (1)
Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). (2022) (1)
The credentialing of American surgery (2006) (1)
BLEOMYCIN-MEDIATED ELECTRO-CHEMOTHERAPY OF METAS-TATIC MELANOMA (1996) (1)
Treatment of the primary malignant melanoma: a review. (1993) (1)
Continuous quality assessment program for the comprehensive breast cancer clinic (1992) (1)
To Dissect or Not To Dissect?—That Is the Question (2002) (1)
"Ultrastaging" of breast cancer in the sentinel lymph node era (2004) (1)
Surgical management of primary melanoma (2000) (1)
Comparison of techniques in locating sentinel nodes in patients with malignant melanoma: 366 (1997) (1)
Letters to the editor [4] (multiple letters) (1998) (1)
Clinical Practice Guidelines: Clinical Practice Guidelines for Melanoma (1997) (1)
Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials (2018) (0)
Conference Preview: Joint Cancer Conference 2000 I. Introduction (1999) (0)
Original scientific articleInvited commentary (2000) (0)
Histopathologic Assessment of Primary Melanomas in Sentinel Node Positive Patients. (1999) (0)
RT-PCR of sentinel lymph node metastases in malignant melanoma patients: 117 (1997) (0)
Early detection of circulating melanoma cells in peripheral blood by RT-PCR: 195 (1997) (0)
Malignant melanoma and pregnancy. (1985) (0)
Commentary on “Assessment of Axillary Lymph Node Involvement in Small Breast Cancer: Analysis of 893 Cases” (2001) (0)
Hyperthermic Isolated Limb Perfusion for (2001) (0)
Should Axillary Lymph Node Dissection be Done for Breast Cancer (2009) (0)
Comparison of radiopharmaceuticals utilized in lymphoscintigraphy: 305 (1997) (0)
A personal computer database for clinical management and research for malignant melanoma: 196 (1993) (0)
QS109. Validation of a Clinical Prediction Rule for Patients' Likelihood of Requiring Post-Mastectomy Radiation Therapy (2009) (0)
LYMPHATIC MAPPING AND SENTINEL NODE BIOPSY IN BREAST CANCER. AUTHORS' REPLY (1997) (0)
A minimal incision approach to inguinal lymphadenectomy: 164 (1997) (0)
The next issue of Cancer Control: Journal of the Moffitt Cancer Center will focus on radioguided surgery for cancer. Among the topics and authors are: (1997) (0)
Intraoperative lymphatic mapping for melanoma: 117 (1993) (0)
Prognosis of Melanoma-Reply (1983) (0)
Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of ≥4 positive (+) lymph nodes (LN). (2009) (0)
Peripheral Soft Tissue Masses: Present Day Diagnosis and Treatment (2018) (0)
An investigational rapid RT-PCR assay for the detection of metastasis in sentinel lymph nodes shows improved performance over frozen section H&E: Analysis by primary tumor characteristics (2007) (0)
Ten Best Readings on Radioguided Surgery: The ten best recent articles in the medical literature relating to radioguided surgery are reviewed here. (1997) (0)
Molecular Staging of Melanoma (1999) (0)
Morning Session H Sentinel Lymp.h Node Biopsy for Breast Cancer: Combined Dye- Isotope Techmque (2000) (0)
Functional and morphologic changes associated with insulinoma transplantation into diabetic rats. (1983) (0)
A case report of invasive ductal adenocarcinoma identified in a lymphatic channel: a staging controversy. (2003) (0)
2008 Cancer Committee Members (2009) (0)
Current management of melanoma patients with nodal metastases (2021) (0)
Malignant melanoma in the pediatric population (2015) (0)
Detection of micrometastases in regional lymph nodes of melanoma patients: 324 (1993) (0)
Surgical Approaches to Cutaneous Melanoma, Vol. 7 in the Pigment Cell Series (1986) (0)
Generation of mathematical model to predict sentinel node involvement in malignant melanoma: 272 (1997) (0)
Ten Best Readings in Melanoma (2002) (0)
Self-assessment examination of the american academy of dermatology (Identification no. 899-211) (2000) (0)
SS6-3 Technical Aspects of Sentinel Node Mapping and Detection of MicroMetastases in Malignant Melanoma and Breast Cancer (2000) (0)
Electrochemotherapy as a treatment for melanoma and other cutaneous malignancies: 110 (1997) (0)
Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma (1985) (0)
The effectiveness of skin cancer screening and continuing education programs towards increasing the survival of patients with melanoma: 199 (1993) (0)
Introduction: the future is now for radioguided surgery (2004) (0)
"Times are changing". (1997) (0)
Commentary on “Comprehensive Review of Sentinel Lymphadenectomy in Breast Cancer” (2000) (0)
Accepted for Plenary & Parallel Sessions (2015) (0)
Is Specimen Mammography Beneficial?—Invited Critique (2000) (0)
Scientific paper Patterns of early recurrence after sentinel lymph node biopsy for melanoma (2002) (0)
A redefinition of skin lymphatic drainage with the use of lymphoscintigraphy: implications for elective node dissection for melanoma (1993) (0)
Breast cancer : conservative approach to the axilla for better staging (1997) (0)
Molecular Staging of Malignant Melanoma (2013) (0)
Will Rogers Phenomenon-Reply (1992) (0)
Non‐Operative Observation of Mammographic Abnormalities: Medical Legal Implications (1995) (0)
The promise of new technologies and therapies. (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Douglas Scott Reintgen?

Douglas Scott Reintgen is affiliated with the following schools: